Facultad de Medicina (FM)
Centro académico
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (182)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial
The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
How Molecular and Ancillary Tests Can Help in Challenging Cytopathology Cases: Insights from the International Molecular Cytopathology Meeting
Journal of Molecular Pathology, Vol. 5, Núm. 2, pp. 228-237
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Nature Communications, Vol. 15, Núm. 1
-
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma
OncoImmunology, Vol. 13, Núm. 1
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
-
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Blood cancer discovery, Vol. 5, Núm. 1, pp. 21-33
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Nature Cancer
2023
-
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature, Vol. 616, Núm. 7957, pp. 563-573
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 2, pp. 328-343
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Nature Medicine
-
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Nature Communications, Vol. 14, Núm. 1